Core Points - The company announced the repurchase and cancellation of 897,140 restricted A-shares due to the departure of certain incentive plan participants and failure to meet performance targets for the 2024 fiscal year [1][2][3] Summary by Sections Reasons for Repurchase and Cancellation - The repurchase and cancellation are due to the departure of 2 initial grant incentive participants and 9 reserved grant incentive participants [2] - The performance targets set for the 2024 fiscal year under the restricted A-share incentive plan were not met, triggering the repurchase and cancellation conditions [1][3] Details of the Repurchase and Cancellation - A total of 897,140 restricted A-shares will be repurchased and canceled, with the repurchase price being the grant price [2][3] - The repurchase includes 37,092 shares from departing incentive participants and 723,248 shares from other participants due to unmet performance targets [3][4] Share Structure Changes - Following the cancellation, the total share capital of the company will decrease from 2,671,326,465 shares to 2,670,429,325 shares [4] - The holding percentage of the controlling shareholder, Fosun High Technology, will slightly increase from 35.99% to 36.00% after the cancellation [4] Compliance and Legal Opinions - The company’s board believes that the decision-making process and information disclosure comply with relevant regulations and does not harm the rights of incentive participants or creditors [4] - Legal opinions confirm that the repurchase and cancellation have obtained necessary approvals and comply with applicable laws and regulations [4][5]
复星医药: 复星医药关于A股限制性股票回购注销实施的公告